What it is, and the one use it's actually approved for
CBD (cannabidiol) is one of over 100 cannabinoids in the cannabis plant. Unlike THC, it carries no intoxicating effect. The FDA has approved one CBD-based drug, Epidiolex, for two rare, severe forms of childhood epilepsy, based on solid randomized trial evidence. That approval is narrow: it covers those seizure conditions and that specific prescription formulation. It doesn't extend to over-the-counter gummies or drops for other uses, even though the same molecule is involved.
What the evidence shows for anxiety
This is where CBD's human trial base is strongest outside epilepsy. Several controlled trials, including one widely cited study using simulated public speaking, found that a single 300mg dose of CBD reduced self-reported anxiety compared to placebo. Lower doses (150mg) and much higher doses (600mg) showed weaker effects in the same trial, suggesting a real but narrow effective range rather than 'more is better.'
This evidence is mostly about acute, situational anxiety rather than chronic anxiety disorders treated daily over months, where the trial base is thinner.
What the evidence shows for sleep
Sleep is CBD's most heavily marketed use and its weakest evidence base of the three covered here. Small trials show mixed results, some report modestly improved sleep scores, others show no significant difference from placebo, and effects that do appear seem to run through reduced anxiety rather than a direct sedative action on sleep architecture itself.
Products combining CBD with CBN or melatonin (common in the gummy market) haven't been tested as combinations in controlled trials, so claims about that specific combination outperforming CBD alone are marketing, not trial data.
Dosing, interactions, and side effects
CBD is processed by the same liver enzyme pathway (CYP450) as a wide range of prescription drugs, including blood thinners and some seizure medications, and can meaningfully change their blood levels. This interaction is well documented and is the single most important safety issue with CBD, more relevant for most people than any side effect of CBD itself.
Reported side effects in trials are generally mild: fatigue, diarrhea, and appetite changes are the most common. Product-to-product potency varies widely in the unregulated consumer market, so the mg-per-serving on a label is worth checking against the trial doses above rather than assuming any 'CBD product' delivers a clinically tested amount.
